{{'Tue, 19 Nov 2024 14:45:00 -0500' | dateFormatUsFilter}}
ESSENCE Phase 3 trial results demonstrating statistically significant and superior improvements with semaglutide 2.4 mg in people with MASH presented at AASLD 2024 - The Liver Meeting®
Read more
{{'Wed, 06 Nov 2024 05:17:00 -0500' | dateFormatUsFilter}}
Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to USD 29.8 billion in the first nine months of 2024
Read more
{{'Sun, 03 Nov 2024 15:30:00 -0500' | dateFormatUsFilter}}
New SELECT trial analysis with semaglutide 2.4 mg showed a significant reduction in hospital admissions in adults with known heart disease and obesity or overweight
Read more
Here are our current job openings. If we don’t currently have an opening in your area of interest, we encourage you to create a job agent and candidate profile.